UBT251
UBT251 (GLP-1/GIP/glucagon triple agonist)
Also known as: UBT-251
Novo Nordisk's licensed triple agonist that produced up to 19.7% weight loss in 24 weeks in a Chinese Phase 2, the company's answer to retatrutide.
Overview
UBT251 was developed by The United Laboratories and licensed by Novo Nordisk outside China. A 24-week Phase 2 reported in February 2026 showed up to 19.7% mean weight loss (17.5 kg) against 2.0% on placebo, and a diabetes Phase 2 reported HbA1c reductions up to 2.16%. Novo dropped its in-house triple agonist despite a positive Phase 2 and is advancing UBT251 instead, with Phase 3 planned in China.
Mechanism of action
Agonism of GLP-1, GIP and glucagon receptors, combining appetite suppression with increased energy expenditure.
Key studies & citations
- Human2026
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in Phase 2 in China
Up to 17.5 kg lost at 24 weeks versus 2.0% on placebo.
Novo Nordisk press release - Human2026
UBT251 reduced HbA1c by up to 2.16% after 24 weeks in type 2 diabetes
Glycemic benefit alongside weight loss.
Novo Nordisk press release
Frequently asked questions
Is UBT251 the same as retatrutide?
No. Both hit GLP-1, GIP and glucagon receptors, but they are different molecules from different companies. Retatrutide has completed Phase 3; UBT251 has 24-week Phase 2 data.